cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Novo's disappoint analysts, sending stock tumbling - MM+M Cagrilintide–semaglutide (CagriSema) as an add-on
Cagrilintidesemaglutide (CagriSema) as an add on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double blind, placebo controlled, multicentre, phase 3 study The Lancet Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Novo Nordisk stock crashes after CagriSema misses phase 3 weight loss goal Fierce Biotech Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits Reuters Coadministered Cagrilintide and Semaglutide, in Adults with Overweight or Obesity. June 22,, 2025. DOI: 10.1056 NEJMoa2502081, CagrilintideSemaglutide in Adults with, Overweight or Obesity and Type 2 Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025
Pay in 4 interest-free payments of $6.65 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
01022-6/asset/8e5594ca-57f9-4753-8b3e-9fa284427e35/main.assets/gr3_lrg.jpg)



